Search
Selected Filter
Filter Results
Displaying 81–90 of 196 research results for “stem-cells”
-
Apr 11, 2024
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
The gene therapy is administered using a less-invasive intravitreal injection.
-
Mar 27, 2024
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
The company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
Nov 8, 2023
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
The company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Aug 5, 2023
IZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to Advanced Dry AMD
In two Phase 3 clinical trials, IZERVAY slowed the growth rate of lesions, the regions of cell loss in the central retina, associated with geographic atrophy (GA)
-
Mar 30, 2023
Most participants with advanced retinitis pigmentosa (RP) in the trial had improved navigation and/or object discrimination in reduced lighting conditions
-
Oct 10, 2022
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Reports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Jul 25, 2022
The emerging therapy is designed to restore vision for people with advanced retinal degenerative diseases
-
Jul 19, 2021
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
While the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
Jun 18, 2020
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Treatment combines gene therapy and a device that generates and delivers retinal code
-
Jan 17, 2018
Clinical Trial to Launch for System Combining Optogenetics and Eyewear
The French biotech GenSight Biologics has received regulatory authorization in the UK to launch the PIONEER Phase 1 \ 2 clinical trial for its GS030 system — a light-sensing gene therapy (optogenetics) coupled with eyewear, which enhances visual stimulation.